Loading
Geneseeq's whole-genome fragment test found most cancers in a laboratory set, and about half, mostly early, in a first prospective group of 3,724 people without symptoms.
Bao and colleagues (Nanjing Geneseeq Technology) evaluated a multi-cancer test using genetic and fragmentomic features from whole-genome sequencing of plasma cell-free DNA. In an internal validation cohort (3,021 with cancer, 3,370 without) and an independent cohort (677 with cancer, 687 without), the independent set gave 87.4% sensitivity, 97.8% specificity and 82.4% tissue-of-origin accuracy. Preliminary results from a prospective study of 3,724 asymptomatic participants showed 53.5% sensitivity, predominantly for early-stage cancers, and 98.1% specificity.
The drop from 87% in known cancers to 54% in people without symptoms is the usual gap between case-control and screening performance, shown in one paper.
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/